Vaccines have been the most successful tool in public health for over 150 years. But up to now they have been generic: each one is raised and designed against a specific disease-such as rabies, smallpox and more recently malaria. A new class of vaccine changes that logic entirely. These are individualised neoantigen vaccines, built from the unique mutations in each patient’s tumour. Today we highlight the first positive Phase 3 results for one of these, as reported by the BBC’s Joe McFadden. [1]
Intismeran is constructed from the mutational “fingerprint” of each patient’s melanoma — a bespoke mRNA vaccine rather than a one‑size‑fits‑all jab. In the Phase 3 INTerpath‑001 trial, jointly run by Merck and Moderna, 1,137 patients with completely resected stage IIB–IV melanoma were randomised to receive either Keytruda (Merck’s anti‑PD‑1 therapy) alone or Keytruda plus Intismeran.[2] [3] This is how Joe summarises the early results:
Early results show this new jab extended the length of time these patients were cancer free, but it’s unclear for how long, according to an announcement by the two firms.
Encouraging, we say: hats off to the companies and scientists involved. As for the wider reaction from the scientific community, it is positive indeed, but we’ll leave it to Joe to tell you about that
At this point we invoke our two favourite LSS tropes: caution and caveat. This is an early-days report: the work must now jump all the usual hoops of peer review, regulatory approval scaling and much more before any kind of routine clinical applications are possible. But there are many reasons to be optimistic, not just about Intismeran, but also certain wider preoccupations of ours. Firstly: some of the best research is done by that happy, hard to define network of companies, research institutes and académe, which has done so much to transform the human condition since the nineteenth century. Secondly, genetic engineering, which we follow avidly here, is in its infancy-this is quite different to our regular antibiotics theme, isn’t it? But most of all, if you want life to really get better, stop believing in what you want to believe and start believing in the scientific method.
[1] Vaccine breakthrough stops cancer returning in trial – BBC News
[3] Merck-Moderna cancer vax slows recurrence in ph. 3 trial
# Intismeran # Keytruda #melanoma #vaccine #mRNA #health #medicine #cancer #reseach #peer review
Learning, Science and Society 